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LPS-Induced Release of IL-1, IL-1Ra, IL-6, and 
TNF- in Whole Blood from Patients with 
Familial Hypercholesterolemia: No Effect 
of Cholesterol-Lowering Treatment
NATASJA DE BONT, MIHAI G. NETEA, CHANTAL ROVERS, TINEKE SMILDE, ANNEKE HIJMANS,
PIERRE N.M. DEMACKER, JOS W.M. VAN DER MEER, and ANTON F.H. STALENHOEF
ABSTRACT
Proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor- (TNF-), are
suggested to have an important role in the process of atherosclerosis. Patients with heterozygous familial hy-
percholesterolemia (FH) have a marked elevation in the plasma level of low-density lipoproteins (LDL), and
they show early development of atherosclerosis. The aim of the present study was to test with a whole blood
culture system if hyperlipoproteinemia is associated with increased cytokine production capacity in these pa-
tients and if treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors influ-
ences this production capacity of blood cells, at both the protein and mRNA levels. The capacity of blood cells
in a whole blood culture to produce IL-1, IL-6, TNF-, IL-12, IL-18, and IL-1 receptor antagonist (IL-1Ra)
in response to lipopolysaccharide (LPS) appeared to be similar for heterozygous FH patients and healthy vol-
unteers. Furthermore, the capacity to produce IL-1, IL-6, and TNF- in response to LPS was not modified
by cholesterol synthesis inhibitors at the level of mRNA expression or at the level of release. On the other
hand, the release of IL-1Ra was significantly increased after treatment with HMG-CoA reductase inhibitors,
although only at the protein level. This suggests a possible beneficial anti-inflammatory role for this therapy.
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INTRODUCTION
ENDOTOXIN, THE LIPOPOLYSACCHARIDE (LPS) component of the outer membrane of gram-negative bacteria, is con-
sidered to be one of the most important mediators in the
pathogenesis of gram-negative sepsis.1 In addition, studies
suggest a role for LPS-induced immune mechanisms in the
development of atherogenesis.2–4 Several mechanisms may
be responsible for initiation of the atherosclerotic lesion. One
such mechanism is the formation of complexes of LPS with
the lipoproteins5 that are transported from the circulation into
the arterial wall, where they initiate an inflammatory re-
sponse.6 In addition, LPS has a macrophage-activating ca-
pacity and can induce oxidation of low-density lipoprotein
(LDL),7 a major mediator in atherogenesis.8,9 The expression
of adhesion molecules can be upregulated by LPS, causing
increased adhesion of monocytes and T cells to the endothe-
lium.10–12 When compared to controls, hypercholesterolemic
animals show more severe and persistent endothelial damage
in response to LPS.13 It is hypothesized that most of these
toxic effects of LPS are mediated by such proinflammatory
cytokines as tumor necrosis factor- (TNF-), interleukin-1
(IL-1), and IL-1, produced by monocytes and macro-
phages.1 It has been postulated that hypercholesterolemia in
combination with LPS may increase the risk of developing
atherosclerosis, with LPS causing the initial endothelial dam-
age and hypercholesterolemia disrupting the normal repair
process.2
Only a few reports deal with cytokine production in hyper-
cholesterolemic hosts. Diet-induced hypercholesterolemia in
rabbits and in mice has been demonstrated to cause increased
LPS-induced TNF production.14,15 In addition, peritoneal mac-
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rophages of LDL receptor-deficient (LDLR/) mice produced
more TNF and IL-1 in response to LPS.16 There was a tendency
toward increased cytokine production by isolated peripheral
blood mononuclear cells (PBMC) of homozygous familial hy-
percholesterolemia (FH) patients,17 and it was demonstrated
that the TNF- production capacity of PBMCs of heterozygous
FH patients was increased when stimulated with high LPS con-
centration.18 On the other hand, at more physiologic LPS doses,
no differences in TNF- or IL-1 production between PBMCs
of heterozygous FH patients and controls were found.19
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitor therapy decreases serum cholesterol levels ef-
fectively and reduces cardiovascular morbidity and mortal-
ity.20,21 Reports investigating the effect of cholesterol synthesis
inhibitors on cytokine production capacity in vitro demonstrated
an inhibitory effect on the production of several cytokines. Lo-
vastatin inhibits LPS-induced expression of proinflammatory
cytokines, such as TNF-, IL-1, and IL-6, in rat primary as-
trocytes, microglia, and macrophages22 and the production of
IL-6 and IL-8 and monocyte chemotactic protein-1 (MCP-1) by
monocytes and human mesangial cells, respectively.23,24 How-
ever, only a few reports describe in vivo effects exerted by cho-
lesterol-lowering therapy on cytokine production. Leirisalo-
Repo et al.18 have shown that hypocholesterolemic treatment
did not alter TNF production by monocytes ex vivo. In accor-
dance with these results, we demonstrated that cholesterol-low-
ering treatment in FH patients also did not influence the pro-
duction of IL-1, IL-1, IL-1 receptor antagonist (IL-1Ra), and
IL-6 by PBMCs.19
Although isolated cell populations can provide useful data,
this is an artificial model compared with a system involving
whole blood. In a whole blood culture, the time course of ex
vivo production of cytokines after LPS stimulation is compara-
ble to that in healthy volunteers after a single LPS injection,25
which stresses the importance of this test. An additional ad-
vantage of using a whole blood culture over studies with pri-
mary cultures or preisolated cells is the maintenance of physi-
ologic metabolite and drug concentrations.
In the present study, we used a whole blood culture to eval-
uate the cytokine production capacity of patients with het-
erozygous FH in response to LPS. The effect of treatment with
cholesterol synthesis inhibitors on this capacity at both the pro-
tein and mRNA levels was studied as well.
MATERIALS AND METHODS
Subjects
Twenty-one heterozygous FH patients and 21 healthy con-
trols (Table 1) participated in the study. The patients were
treated with inhibitors of cholesterol synthesis. To exclude a di-
rect interaction of this medication with our assays, cholesterol-
lowering treatment was stopped 2 days before draining blood
samples in the first series of experiments. For 12 patients, the
controls consisted of family members (siblings and parents),
and for the other patients, the controls were age-matched and
weight-matched healthy volunteers from hospital personnel. No
differences in lipid levels and cytokine production between the
group of family members and the group of hospital personnel
were found (data not shown). There were no significant differ-
ences in age or weight between patients and controls.
In a second series of experiments, another 27 heterozy-
gous, DNA-proven FH patients (12 men and 15 women, age
44.5  9.7 years, weight 74.2  9.3 lbs.), who had already
participated in a clinical trial, were examined to investigate
the direct effects of cholesterol-lowering treatment. These pa-
tients stopped hypolipidemic medication 8 weeks before the
study. Subsequently, the FH subjects were treated, double-
blind, with either simvastatin (40 mg daily) or atorvastatin
(80 mg daily). Blood samples were obtained just before and
8 weeks after starting the treatment. None of the patients or
controls received immunosuppressive therapy during the
course of the study, and they had no systemic illnesses that
might have influenced the immune system (e.g., diabetes mel-
litus, rheumatoid arthritis, malignancy). None of the patients
or controls had infections in the 2 weeks before testing, and
they were all requested to fast overnight. The study was ap-
proved by the local ethical committee, and written informed
consent was obtained from all participants before being en-
rolled in the study.
Serum lipid measurements
Serum levels of total cholesterol, high-density lipoprotein
(HDL)-cholesterol, and triglycerides were determined enzy-
matically on a Hitachi 747 (Basel, Switzerland) analyzer.26
LDL-cholesterol levels were calculated according to the Friede-
wald method.27
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TABLE 1. CHARACTERISTICS OF FIRST COHORT OF HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA (FH) PATIENTS VS. CONTROLS
FH Controls p
n 21 21 n.s.a
Male/female 12/9 10/11 n.s.
Age, years 46.7  15.8b 39.6  15.6 n.s.
Weight (kg) 75.7  13.6 71.3  9.5 n.s.
Total cholesterol (mmol/L) 7.6  1.6 5.5  0.9  0.001
LDL-cholesterol (mmol/L) 5.8  1.6 3.7  0.9  0.001
HDL-cholesterol (mmol/L) 1.18  0.35 1.26  0.20 n.s.
Triglycerides (mmol/L) 1.71  0.91 1.21  0.54 0.03
ans, not significant.
bMean  S.D.
Blood samples
Blood from 1 heterozygous FH patient and 1 control was
drawn at the same time and tested simultaneously. Blood from
the group of heterozygous FH patients in the second experi-
ment was drawn just before and 8 weeks after starting hy-
polipidemic medication. Samples were collected into 2-mL (for
ex vivo production) endotoxin-free tubes containing EDTA 
(Vacutainer Systems, Becton Dickinson, Rutherford, NJ). To
study the circulating cytokine concentration, one tube was cen-
trifuged immediately at 2250g for 10 min, followed by centrifu-
gation of the plasma at 15,000g for 5 min to remove platelets.
Whole blood stimulation
Cytokine production was measured using a whole blood cul-
ture system as described elsewhere.28 Briefly, blood was drawn
into two 2-mL tubes containing 24 L EDTA-K3 (Vacutainer
Systems, Becton and Dickinson). One tube was incubated im-
mediately, and the other tube was incubated after the addition
of 50 L LPS (Escherichia coli serotype 055:B5, final con-
centration 10 g/mL blood) (Sigma, St. Louis, MO). After 24
h incubation in a waterbath at 37°C, the tubes were centrifuged
as described. Plasma was used for cytokine protein determina-
tion. In the second group of heterozygous patients, the tubes
were centrifuged after 4 h of incubation at 37°C, as this is the
optimal stimulation period for cytokine mRNA measurement.
After removing the plasma by centrifugation at 2250g for 10
min, aliquots of 500 L cell-pellet were taken, and an equiva-
lent volume of guanidinium-isothiocyanate (GITC), enriched
with 7 L -mercaptoethanol per ml, was added for isolation
of total RNA.29
Cytokine measurements
IL-1, IL-1Ra, and TNF- concentrations were determined
using thoroughly validated radioimmunoassays as described
previously.30 IL-6 concentrations were determined using a
sandwich enzyme immunoassay (Pelikine Compact, CLB, Am-
sterdam, The Netherlands), and IL-12 and IL-18 were measured
by commercial ELISA kits (R&D, Abbingdon, U.K.). In order
to correct for spontaneous cytokine release, the net production
was calculated by subtracting the concentrations without stim-
ulus from those induced by LPS.
mRNA expression
Total RNA was isolated as described previously. The amount
and quality of RNA were determined by spectrophotometry. RT-
PCR for IL-1, TNF-, and 2-microglobulin (2m) was per-
formed as described extensively elsewhere. The RT-PCRs for IL-
1Ra and IL-6 were performed similarly (30 sec denaturation at
92°C, 30 sec annealing at 55°C, and 90 sec extension at 72°C).
To remain in the linear range of the reaction, 25 and 28 cycles,
respectively, were run. The sequences of the PCR primers we
used are listed in Table 2. To correct for fluctuations in leuko-
cyte count, IL-1, IL-1Ra, IL-6, and TNF- mRNA concentra-
tions in a sample were expressed as a ratio vs. the amount of
mRNA of the housekeeping gene 2m. To correct for sponta-
neous cytokine mRNA expression, the net production was cal-
culated by subtracting the expression rate without stimulus from
the expression rate induced by LPS. To minimize analytic vari-
ation, samples before and after 8 weeks of medication were tested
in duplicate in the same series of PCRs.
Statistical analysis
Data are expressed as mean  SD. Statistical analysis was
performed using a Wilcoxon test for paired or unpaired data.
Probability (p) values were calculated on the basis of two-tailed
tests. A p  0.05 was considered significant.
RESULTS
Lipid concentrations
Total plasma cholesterol, LDL-cholesterol, and total triglyc-
eride concentrations were significantly higher in heterozygous
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TABLE 2. PRIMER PAIRS USED FOR MRNA AMPLIFICATION
Fragment Annealing
Primer Sequence length temperature Cycles
2m
Sense 5-CCAGCAGAGAATGGAAAGTC-3 268 55 26
Antisense 5-GATGCTGCTTACATGTCTCG-3
TFN-
Sense 5-ACAAGCCTGTAGCCCATGTT-3 427 55 29
Antisense 5-AAAGTAGACCTGCCCAGACT-3
IL-1
Sense 5-GGATATGGAGCAACAAGTGG-3 263 55 29
Antisense 5-ATGTACCAGTTGGGGAACTG-3
IL-1RA
Sense 5-CTTCTATCTGAGGAACAACC-3 158 55 25
Antisense 5-TCATCACCAGACTTGACACA-3
IL-6
Sense 5-CACCTCTTCAGAACGAATTG-3 314 55 28
Antisense 5-GGATCAGGACTTTTCTACTC-3
FH patients vs. controls, whereas no difference in plasma HDL-
cholesterol was found (Table 1). In the second cohort, total
plasma cholesterol, LDL-cholesterol, and triglyceride concen-
trations were significantly decreased (42%, 49%, and 31%, re-
spectively) after hypocholesterolemic treatment, whereas HDL-
cholesterol concentrations were slightly, yet significantly,
increased (5%) (Table 3).
Cytokine production
LPS-stimulated cytokine production capacity ex vivo
(mean  SD) was within the normal range. Circulating con-
centrations of IL-1, IL-1Ra, IL-6, and TNF- and cytokine
production of unstimulated whole blood cultures were very low
and did not differ between patients and controls after choles-
terol-lowering treatment (data not shown).
To overcome variable neutralization of LPS by lipopro-
teins,5] cytokine production in the whole blood cultures from
FH patients and controls was assessed at an excess LPS con-
centration of 10 g/mL. To examine the influence of hyperc-
holesterolemia on the cytokine production capacity, production
of the proinflammatory cytokines IL-1, IL-6, and TNF- and
the anti-inflammatory cytokine IL-1Ra in a whole blood cul-
ture was measured. Cytokine production capacity was compa-
rable between the cultures of FH patients and controls (Table
4). As HMG-CoA reductase inhibitors have been shown to de-
crease cytokine production in vitro, we investigated any dif-
ference in the ex vivo cytokine production capacity of het-
erozygous FH patients as a result of the hypolipidemic
treatment. IL-1Ra concentrations in the whole blood culture 4
h after LPS administration were slightly, albeit significantly,
increased, but production of IL-1, IL-6, and TNF- was sim-
ilar before treatment and 8 weeks after treatment began (Table
5). IL-12 and IL-18 concentrations, important Th1-type in-
flammatory mediators in atherosclerosis, were in most patients
below the detection limit and not different between groups (data
not shown).
Cytokine mRNA expression
The cytokine level found in the plasma after culturing whole
blood is the net concentration obtained after subtracting the up-
take of cytokines by the cells from the actual production. For
insight into the production of cytokines, we also investigated
the effect of HMG-CoA reductase inhibitors on transcription of
cytokines. The HMG-CoA reductase inhibitors did not influ-
ence the expression of mRNA for IL-1, IL-1Ra, IL-6, and
TNF- (Table 6), and the concentrations of IL-12 and IL-18
were below the detection limit.
DISCUSSION
Proinflammatory cytokines are suggested to have a role in
LPS-mediated endothelial damage,1 in the uptake of oxidized
LDL through increased expression of macrophage scavenger
receptors,31 and in regulating the plaque stability.32 Each of
these may be important in the process of atherosclerosis.33 Nev-
ertheless, it is important in which compartment the cytokines
are produced. In plasma, TNF and IL-1 may induce endothe-
lial cell damage,2 whereas cytokines produced in the athero-
sclerotic plaque can stimulate cell proliferation and migration
of smooth muscle cells and macrophages,33 and decrease the
stability of the plaque.32 We investigated whether the blood
cells of patients with FH have an increased cytokine produc-
tion capacity in comparison to normocholesterolemic controls,
which would reflect the cytokine-mediated endothelial damage.
In the present study, whole blood production capacity for the
cytokines IL-1, TNF-, IL-6, and IL-1Ra was similar in het-
erozygous FH patients and controls, consistent with the results
found for PBMCs isolated from these subjects, and stimulated
with a lower and more physiologic dose of LPS.17–19 However,
Leirisalo-Repo et al.18 reported that at much higher LPS con-
centrations, comparable to the concentrations used in our whole
blood culture, TNF production by monocytes of heterozygous
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TABLE 4. PRODUCTION OF CYTOKINES IN WHOLE BLOOD
CULTURE OF HETEROZYGOUS FH PATIENTS AND CONTROLS
AFTER STIMULATION WITH 10 G/ML LPS FOR 24 H
FH (ng/mL) Controls (ng/mL)
IL-1 8.9  4.9a 9.6  3.3
IL-1RA 8.8  1.4 10.0  2.2
IL-6 24.0  8.8 21.7  7.5
TFN- 3.8  2.0 4.0  1.9
aMean  SD. Net production was calculated by subtracting
the concentrations without stimulus from the concentrations 
induced by LPS.
TABLE 3. CHARACTERISTICS OF SECOND COHORT OF HETEROZYGOUS FH PATIENTS
BEFORE AND AFTER CHOLESTEROL-LOWERING TREATMENT
Characteristic Before medication After medication p-value
n 27 27
Male/female 12/15 12/15
Age, years 44.5  9.7a 44.5  9.7
Weight (kg) 74.2  9.3 74.2  9.3
Total cholesterol (mmol/L) 11.37  1.8 6.60  1.53  0.001
LDL-cholesterol (mmol/L) 9.40  1.75 4.81  1.50  0.001
HDL-cholesterol (mmol/L) 1.16  0.31 1.22  0.3  0.041
Triglycerides (mmol/L) 1.99  0.92 1.37  0.67  0.001
aMean  S.D.
FH patients was increased,18 in contrast to our observations. In
both studies, the medication was stopped 24–48 h before test-
ing. The differences between these results possibly are depen-
dent on the different methods used: PBMCs vs. whole blood
culture, the latter more closely approaching the native envi-
ronment of blood cells. Several substances present in the cir-
culation, such as hormones, antioxidants, and lipids, will be pre-
served in a whole blood culture. All these substances may affect
the immunologic responses of the cells and, in addition, have
interactions with LPS. Moreover, the cell to cell interaction is
very important, as the release of cytokines by certain cells can
inhibit production by other cells. We cannot exclude, however
that in FH patients, a source other than blood cells, such as tis-
sue macrophages, endothelial cells, smooth muscle cells, or
liver cells, has increased cytokine production capacity.
Diet-induced hypercholesterolemic rabbits and mice demon-
strated increased LPS-induced TNF production as well.14,15 It
is questionable whether results obtained in rodents can be ex-
trapolated to humans, especially when the hypercholesterolemia
is of exogenous instead of endogenous origin. Furthermore, the
immunologic response may vary with the type and physical
state of the LPS, as demonstrated for LPS-binding protein
(LBP) binding capacity, which was different for LPS derived
from Salmonella34 and LPS derived from E. coli.35 The diet-
induced hypercholesterolemia in rabbits was more profound
than the hypercholesterolemia in our group of patients.14 Such
an extreme hypercholesterolemia in these rabbits might have
caused an increased rate of oxidation, rendering them more sus-
ceptible to LPS.
HMG-CoA reductase inhibitors are at present the first choice
of drugs to decrease elevated levels of plasma cholesterol, as
these agents decrease serum cholesterol levels effectively and,
moreover, reduce cardiovascular morbidity and mortality.20,21
Inhibitors of HMG-CoA reductase reportedly inhibited the pro-
duction of several cytokines in vitro.22–24 Pahan et al.22 dem-
onstrated that the LPS-induced expression of TNF-, IL-1,
and IL-6 in rat primary astrocytes, microglia, and macrophages
was inhibited by 10 M lovastatin, and others showed that the
production of IL-6 and IL-8 by THP-1 cells was suppressed af-
ter compactin treatment (10 M).23 Therefore, we determined
whether in vivo administration of these drugs can also inhibit
the production of cytokines. Using a whole blood culture, we
were not able to confirm these findings; the capacity of blood
cells to produce IL-1, IL-6, TNF-, IL-12, and IL-18 was in-
dependent of the treatment, at the level of both protein con-
centration and mRNA expression.
An important difference in our study was the dose of HMG-
CoA reductase used in these in vitro studies, which is more than
a hundred times higher than the physiologic peak plasma con-
centration of 0.07 M found in humans.36 Furthermore, the
methods and the origin of the cells used for assessing cytokine
production are not comparable.
On the other hand, our results support the observations that
treatment of FH patients with inhibitors of HMG-CoA reduc-
tase does not influence the capacity of their PBMCs to produce
proinflammatory cytokines in response to LPS.18,19 The results
obtained with PBMCs particularly showed the indirect effect of
inhibitors of HMG-CoA reductase on cytokine production ca-
pacity, as the drug was no longer present in the culture. In ad-
dition, our results demonstrate that HMG-CoA reductase in-
hibitors do not have any direct influence on the capacity of
blood cells to produce proinflammatory cytokines. Neverthe-
less, this does not exclude possible direct effects by HMG-CoA
reductase inhibitors on in vivo mechanisms. Although we used
a system that closely resembles the in vivo situation, there are
still many compartments in vivo that could be triggered by these
drugs. Cholesterol synthesis inhibitors act mainly in the liver
and the intestine, where they inhibit the activity of the enzyme
HMG-CoA reductase by about 90%.37,38
In contrast to the capacity to produce proinflammatory cy-
tokines, blood cells of patients treated with cholesterol synthe-
sis inhibitors can produce significantly more of the anti-
inflammatory cytokine IL-1Ra. However, the IL-1Ra mRNA
expression did not change. Apparently, HMG-CoA reductase
inhibitors affect the direct release of this cytokine but not the
mRNA expression after 4 h. It may be possible that the effect
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TABLE 5. PRODUCTION OF CYTOKINES IN WHOLE BLOOD CULTURE AFTER STIMULATION WITH
10 G/ML LPS FOR 4 H BEFORE AND DURING TREATMENT TO DECREASE CHOLESTEROL
Before medication (ng/mL) After medication (ng/mL)
IL-1 7.0  3.2a 6.5  2.3
IL-1RA 6.1  1.3 6.5  1.6*
IL-6 9.8  4.8 9.3  4.6
TFN- 3.1  1.3 3.3  2.0
aMean  SD. Net production was calculated by subtracting the concentrations without stimulus from the concentrations 
induced by LPS.
*p  0.05.
TABLE 6. MRNA EXPRESSION OF CYTOKINES IN WHOLE
BLOOD CULTURE 4 H AFTER LPS STIMULATION BEFORE AND
AFTER 8 WEEKS OF CHOLESTEROL-LOWERING TREATMENT
Ratioa Before medication After medication
IL-1/2m 2.0  0.5 1.9  0.5
IL-1RA/2m 1.0  0.2 0.9  0.2
IL-6/2m 1.6  0.5 1.6  0.5
TFN-/2m 1.6  0.6 1.5  0.6
aRatio of cytokine mRNA/mRNA expression of the house-
keeping gene 2m. Net mRNA expression was calculated by
subtracting the concentrations without stimulus from the con-
centrations induced by LPS.
of HMG-CoA reductase inhibitors on the release of this anti-
inflammatory cytokine may be more important than its effect
on proinflammatory cytokines. It has been suggested that IL-
1Ra plays a pharmacologic role in inhibiting vascular smooth
muscle cell proliferation, possibly by interfering with the au-
tocrine regulatory pathway of IL-1.39 It has been demonstrated
that IL-1Ra also inhibits IL-1-induced adhesiveness of human
vascular smooth muscle cells for monocytes and neutrophils.10
Both these mechanisms are important in the process of athero-
sclerosis, but it should be noted that the increase in IL-1Ra con-
centrations was minimal, and its biologic relevance remains to
be demonstrated.
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